Table 2.

The clinical progress of TNFR2-Targeting Treatment antibody research and development.

Antibody	Company name	Country	Character	Clinicalphase	Function	Indication	Ref.
BITR2101	BeiGene	China	McAb	I	TNFR2 Antagonist	cancer/infection	BeiGene
AN3025	Adlai Nortye Biopharma	China	McAb	Preclinical	TNFR2 antibody that exhibits immune activation and strong anti-tumor activity in vivo and can enhance anti-tumor efficacy of mPD-1 antibody in a combination study	Cancer	AACR
SIM0235 (SIM1811-03)	Simcere Pharmaceutical	China	McAb	I	This antibody can specifically recognize TNFR2 expressed on the surfaces of tumor cells and directly kill tumors.	Advanced solid cancer, cutaneous T-cell lymphoma	AACR
BITR2101	BITT	Boston	McAb	I	TNFR2 antagonist	Cancer/infection	BITT
BI-1808	BioInvent	Sweden	McAb	I	Ligand-blocking T reg depleting antibody	Advanced malignancies	Clinicaltrials .gov
BI-1910	BioInvent	Sweden	McAb	Preclinical	TNFR2 agonist antibody	Advanced malignancies	AACR
HFB200301	HiFiBiO Therapeutics	USA	McAb	I	Anti-TNFR2 agonist antibody with Fc-independent agonist activity that does not block TNFR2 interactions with TNFα	Cancer	AACR
APX601	Apexigen	USA	McAb	Preclinical	TNFR2 antagonist; can inhibit Treg and myeloid suppressive cells and reverse immune suppression in the TME and inhibit tumor growth	Solid cancer	AACR
MM-401	Merrimack Pharmaceuticals	USA	McAb	Preclinical	TNFR2 antibody that has agonistic activity and induces TNFR2 signaling and can also promote anti-tumor immunity by mediating effects of ADCCs, as well as via direct co-stimulation of T cell responses	Cancer	AACR

BITT, indicate as Boston Immune Technologies and Therapeutics; McAb, monoclonal antibody; ADCC, antibody-dependent cellular cytotoxicity; AACR, American Association for Cancer Research; Clinicaltrials.gov, https://clinicaltrials.gov/.